FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
|Articles|May 5, 2010
Blumenfield bio info
Michael Blumenfield, MD, is The Sidney E. Frank Distinguished Professor Emeritus of Psychiatry and Behavioral Sciences at New York Medical College. He is a Past Speaker of the Assembly of the American Psychiatric Association. Dr Blumenfield lives and practices in Woodland Hills, Calif, where he also writes the weekly blog, PsychiatryTalk.com.
Advertisement
Michael Blumenfield, MD, is The Sidney E. Frank Distinguished Professor Emeritus of Psychiatry and Behavioral Sciences at New York Medical College. He is a Past Speaker of the Assembly of the American Psychiatric Association. Dr Blumenfield lives and practices in Woodland Hills, Calif, where he also writes the weekly blog,
Advertisement
Related to this article
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
How past “untreatable” labels mislead psychiatry—and why measurement-informed care and difficult-to-treat depression replace today’s treatment-resistant mindset.
There is a question older than medicine, and perhaps older than philosophy, that psychiatry has largely avoided: What makes us human?
APSARD is preparing US adult ADHD guidelines, delivering long-awaited screening, diagnosis, and treatment recommendations as experts discuss the upcoming release.
Review top pipeline updates from last week.
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
2
The New, Impending Adult ADHD Guidelines
3
Reframing “Treatment-Resistant” as “Difficult-To-Treat”
4
Formulations Matter: The Approval of Olanzapine Extended-Release Injectable Suspension for Schizophrenia
5